TerminatedNot Applicable

Aripiprazole Treatment of the Prodrome

Stopped: The study was terminated due to low enrollment.

United States30 participantsStarted 2004-01

Plain-language summary

The RAP Program is conducting a research study of the antipsychotic medication Aripiprazole. This drug has been approved for treating symptoms associated with schizophrenia and is associated with fewer side effects. This study will explore how well Aripiprazole treats symptoms of early-onset psychotic disorders as well as symptoms that may indicate risk for such disorders, including unusual thoughts, suspiciousness, perceptual abnormalities, social isolation, and sudden changes in functioning.

Who can participate

Age range13 Years – 22 Years

SexALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion Criteria: * You are between the ages of 13 and 22. * You are English-speaking. * You have a diagnosed psychotic disorder, including: schizophrenia, schizophreniform disorder, schizoaffective disorder, or other psychotic disorder * OR - * You are experiencing one or more pre-psychotic symptoms like unusual thoughts, suspiciousness, or unusual perceptual experiences. * You meet additional RAP criteria assessed during screening and interview. Exclusion Criteria: * You have a diagnosis of bipolar disorder or major depression with psychotic features. * You have a history of neurological, neuroendocrine, or other medical conditions known to affect the brain. * You have past or current substance dependence. * You are currently taking Aripiprazole. * You have taken Aripiprazole in the past. * You are currently taking and responding well to another medication.

What they're measuring

Score on attenuated positive symptom scale at 12 weeks

Score on attenuated negative symptom scale at 12 weeks

Score on adverse events rating scale at 12 weeks

Trial details

NCT IDNCT00169949

SponsorNorthwell Health

Sponsor typeOTHER

Study typeINTERVENTIONAL